Leerink Partnrs Has Weak Forecast for enGene FY2029 Earnings

enGene Holdings Inc. (NASDAQ:ENGN) – Analysts at Leerink Partnrs reduced their FY2029 earnings estimates for shares of enGene in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will earn $0.57 per share for the year, down from their previous estimate of $0.60. The consensus estimate for enGene’s current full-year earnings is ($1.57) per share.

ENGN has been the subject of several other research reports. Raymond James initiated coverage on shares of enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective for the company. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. HC Wainwright assumed coverage on shares of enGene in a research note on Monday, December 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of enGene in a research report on Monday, December 23rd. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, enGene presently has a consensus rating of “Buy” and an average price target of $29.78.

enGene Stock Performance

Shares of NASDAQ:ENGN traded up $0.09 on Thursday, hitting $7.04. The company’s stock had a trading volume of 2,455 shares, compared to its average volume of 91,959. The company has a market capitalization of $311.09 million, a price-to-earnings ratio of -12.13 and a beta of -0.65. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. enGene has a 12 month low of $4.42 and a 12 month high of $18.40. The stock’s 50-day moving average is $7.39 and its two-hundred day moving average is $7.54.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06.

Institutional Investors Weigh In On enGene

Several hedge funds have recently modified their holdings of the stock. Wolverine Asset Management LLC purchased a new stake in enGene during the third quarter valued at about $37,000. Point72 Asset Management L.P. grew its position in enGene by 1,410.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after purchasing an additional 619,100 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the period. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.